Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

BACKGROUND: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gualberto, A, Hixon, M L, Karp, D D, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, L G, Novello, S, Blakely, J, Langer, C J, Pollak, M N
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3039819/
https://ncbi.nlm.nih.gov/pubmed/21102589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605972
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados